For neuromyelitis optica spectrum disorder, long-term follow-up with a second-generation complement inhibitor shows an ...

Imagine yourself soaking up the Hawaiian sun after a day of surfing, trekking along volcanic paths, or strolling through ...

Most people with relapsing MS who were treated with Briumvi for six years did not have confirmed disability progression, a study found.

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...